Browse Technologies

Displaying 11 - 20 of 22

Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.

Licensing Contact

Tom Utley

615.343.3852

Inventors

Heidi Hamm, Summer Young, Craig Lindsley, Shaun Stauffer, Matthew Duvernay, Kayla Temple, Wandong Wen
Category:
Therapeutics
Field of Use:
Cardiovascular

Small Molecule Mediated Transcriptional Induction of E-Cadherin and Inhibition of Epithelial-to-mesenchymal Transition

Licensing Contact

Tom Utley

615.343.3852

Inventors

Craig Lindsley, Alex Waterson, Robert Beauchamp
Category:
Therapeutics
Field of Use:
Oncology

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.

Licensing Contact

Tom Utley

615.343.3852

Inventors

Craig Lindsley, P. Jeffrey Conn, Kyle Emmitte, Julie Engers, Leah Konkol
Category:
Therapeutics
Field of Use:
Neuroscience/Neurology Oncology

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).

Licensing Contact

Tom Utley

615.343.3852

Inventors

Craig Lindsley, P. Jeffrey Conn, Kyle Emmitte, Julie Engers, Leah Konkol
Category:
Therapeutics
Field of Use:
Neuroscience/Neurology Oncology

Targeted photodynamic therapy for S. aureus infections

Vanderbilt researchers have developed a combination photodynamic therapy (PDT) for targeting MRSA infections in skin that is not only effective but also HIGHLY SPECIFIC and LESS SUSCEPTIBLE TO RESISTANCE, adding a much needed therapy to our quickly depleting arsenal against this pathogen.

Licensing Contact

Cameron Sargent

615.343.2430

Inventors

Eric Skaar
Category:
Therapeutics
Field of Use:
Dermatology Infectious Disease

Cell-Permeable Socs Proteins That Inhibit Cytokine-Induced Signaling

Scientists at Vanderbilt have developed a unique polypeptide using cell-penetrating SOCS polypeptides or SOCS sequences designed to inhibits cytokine signaling and thus prevent or treat inflammation or an inflammatory related disease such as diabetes. This strategy has been validated in NOD mice models for either induced or naturally occurring diabetes and have been efficacious.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Jack Hawiger, Daewoong Jo
Category:
Therapeutics

Protein that protects probiotics from desiccation, leading to improved gut colonization

Probiotic supplements undergo significant water loss before consumption, killing many of their bacteria and rendering them less effective. Vanderbilt researchers have discovered a protein that protects against damage caused by desiccation and shown that this molecular shield can be added to probiotics to help them survive and colonize the gut. This platform technology can be broadly incorporated into new or existing supplements to make them more efficacious and even improve costs and distribution.

Licensing Contact

Karen Rufus

615.322.4295

Inventors

Eric Skaar, Erin Green
Category:
Therapeutics

An Ergothioneine PET Radioligand for Imaging Oxidative Stress in Alzheimer's Disease

Vanderbilt researchers lead by Professor Wellington Pham, PhD, have developed a novel ergothioneine (ERGO) PET radioligand for imaging oxidative stress in Alzheimer's disease.

Licensing Contact

Masood Machingal

615.343.3548

Inventors

Wellington Pham, William Behof, Clayton Whitmore, Dmitry Koktysh, Justin Haynes
Category:
Therapeutics
Field of Use:
Neuroscience/Neurology

Cooling-Responsive Gel for Local Drug Delivery Applications

Vanderbilt researchers have created a cooling-responsive gel implant that meets the need for non-invasive local drug delivery and is simple to activate, requiring only an ice pack for some applications, eliminating complex clinical equipment. This implant is ideal for alternative pain management or delivery of cancer therapeutics.

Licensing Contact

Philip Swaney

615.322.1067

Inventors

Leon Bellan
Category:
Therapeutics

Small Molecule-GIRK Potassium Channel Modulators That Are Anxiolytic Therapeutics

The G-protein activated, inward-rectifying potassium (K+) channels, "GIRKs", are a family of ion channels that has been the focus of intense research interest for nearly two decades. GIRK has been shown to play important roles in the pathophysiology of diseases such as anxiety, epilepsy, Down's syndrome, pain perception and drug addiction. Here scientists at Vanderbilt developed the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810) and demonstrated that ML297 is active in animal models of epilepsy. While the group is using ML297 to continue to explore the therapeutic benefits of GIRK modulation, they are continuing to develop more selective and druggable GIRK inhibitors from different scaffolds.

Licensing Contact

Tom Utley

615.343.3852

Inventors

Charles Weaver, P. Jeffrey Conn
Category:
Therapeutics
Field of Use:
Analgesic